{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:17:49Z","timestamp":1788185869415,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["207503"],"award-info":[{"award-number":["207503"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The randomized, phase 3 DREAMM-7 trial (NCT04246047) previously demonstrated the efficacy and safety of belantamab mafodotin, bortezomib, and dexamethasone (BVd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed\/refractory multiple myeloma (RRMM) and\u2009\u2265\u20091 prior therapy. The results in the Japan expansion cohort of DREAMM-7, consisting of 24 patients randomized to receive BVd (N\u2009=\u200910) or DVd (N\u2009=\u200914), are presented here. The median follow-up was 19.4\u00a0months (range, 1.3\u201330.3). Median progression-free survival (PFS) was not reached (NR; 95% CI, 7.0\u2013NR) with BVd versus 11.1\u00a0months (95% CI, 4.9\u2013NR) with DVd (PFS hazard ratio, 0.40; 95% CI, 0.11\u20131.52). The overall response rate was 90.0% (95% CI, 55.5\u201399.7) versus 71.4% (95% CI, 41.9\u201391.6); median duration of response was NR (95% CI, 9.7\u2013NR) versus 14.5\u00a0months (95% CI, 3.5\u2013NR). Safety trends in the Japan expansion cohort were similar to those in the global cohort. Ocular adverse reactions were more common with BVd and were manageable with dose modification. No new safety signals were reported. As in the global cohort, results in the Japan expansion cohort demonstrated the safety and efficacy of BVd in patients with RRMM and\u2009\u2265\u20091 prior therapy.<\/jats:p>","DOI":"10.1007\/s12185-026-04211-4","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:05:52Z","timestamp":1776276352000},"page":"370-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial"],"prefix":"10.1007","volume":"124","author":[{"given":"Tomoaki","family":"Fujisaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohmei","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeko","family":"Yonekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Eccersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hena","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2420-2200","authenticated-orcid":false,"given":"Taku","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4211_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1182\/hematology.2024000581","volume":"2024","author":"SK Kumar","year":"2024","unstructured":"Kumar SK. What is the ideal approach-doublet, triplet, or quadruplet(s)? Hematology Am Soc Hematol Educ Program. 2024;2024:551\u201360.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4211_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116192","volume":"25","author":"CH-T Lin","year":"2024","unstructured":"Lin CH-T, Tariq MJ, Ullah F, Sannareddy A, Khalid F, Abbas H, et al. Current novel targeted therapeutic strategies in multiple myeloma. Int J Mol Sci. 2024;25:6192.","journal-title":"Int J Mol Sci"},{"key":"4211_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315932","volume":"20","author":"S Iida","year":"2025","unstructured":"Iida S, Yasutomi Y, Samyshkin Y, Chen YC, Chen CC, Lee WS, et al. Characteristics and treatment patterns in patients with multiple myeloma in Japan: a retrospective cohort analysis. PLoS ONE. 2025;20:e0315932.","journal-title":"PLoS ONE"},{"key":"4211_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14796694.2025.2460419","volume":"21","author":"Y Yasutomi","year":"2025","unstructured":"Yasutomi Y, Ribbands A, Luke E, McNamara S. Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey. Future Oncol. 2025;21:681\u201390.","journal-title":"Future Oncol"},{"key":"4211_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116.","journal-title":"Blood Cancer J"},{"key":"4211_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"key":"4211_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005.","journal-title":"Leukemia"},{"key":"4211_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/curroncol28010063","volume":"28","author":"G Lassiter","year":"2021","unstructured":"Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, et al. Belantamab Mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects. Curr Oncol. 2021;28:640\u201360.","journal-title":"Curr Oncol"},{"key":"4211_CR9","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"4211_CR10","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2147\/DDDT.S267404","volume":"15","author":"MA-O Offidani","year":"2021","unstructured":"Offidani MA-O, Corvatta L, Mor\u00e8 S, Olivieri A. Belantamab Mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety. Drug Des Devel Ther. 2021;15:2401\u201315.","journal-title":"Drug Des Devel Ther"},{"key":"4211_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112948","volume":"15","author":"S Mor\u00e8","year":"2023","unstructured":"Mor\u00e8 S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab Mafodotin: from clinical trials data to real-life experiences. Cancers (Basel). 2023;15:2948.","journal-title":"Cancers (Basel)"},{"key":"4211_CR12","unstructured":"GSK. Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed\/refractory multiple myeloma. News release. (2025). Accessed May 30, 2025. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-japan\/."},{"key":"4211_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med"},{"key":"4211_CR14","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. (2025):S1470-2045(25)00330-4. Online ahead of print."},{"key":"4211_CR15","unstructured":"\u56fd\u7acb\u7814\u7a76\u958b\u767a\u6cd5\u4eba\u56fd\u7acb\u304c\u3093\u7814\u7a76\u30bb\u30f3\u30bf\u30fc. [Statistics by cancer type: Multiple myeloma]. (2025). https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/26_mm.html#anchor1."},{"key":"4211_CR16","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"4211_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28\u201335.","journal-title":"JAMA Oncol"},{"key":"4211_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clml.2024.03.003","volume":"24","author":"E Kastritis","year":"2024","unstructured":"Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, Migkou M, Roussou M, Malandrakis P, et al. Characteristics and outcomes of patients with relapsed\/refractory multiple myeloma after exposure to Lenalidomide in first line of therapy: a single center database review in Greece. Clin Lymphoma Myeloma Leuk. 2024;24:468\u201377.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4211_CR19","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2024.42.16_suppl.7503","volume":"42","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Robak P, Hus M, Fu C, Zherebtsova V, Ward C, et al. DREAMM-7 update: subgroup analyses from a phase 3 trial of Belantamab Mafodotin (belamaf) + Bortezomib and Dexamethasone (BVd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42:7503.","journal-title":"J Clin Oncol"},{"key":"4211_CR20","unstructured":"Hungria V, Robak P, Hus M, Fu C, Zherebtsova V, Ward C, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in relapsed\/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 DREAMM-7 Trial. 21st international myeloma society annual Meeting. Sep 25\u201328, 2024 (2024). Rio de Janeiro, Brazil."},{"key":"4211_CR21","unstructured":"Hungria V, Robak P, Hus M, Fu C, Zherebtsova V, Ward C, et al. Characterization and management of ocular events in patients (Pts) treated with Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 study. 21st International myeloma society annual meeting. Sep 25\u201328, 2024. (2024). Rio de Janeiro, Brazil. https:\/\/imsannual2024.eventscribe.net\/fsPopup.asp?PosterID=692874&mode=posterInfo."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04211-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:37Z","timestamp":1788184597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04211-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4211"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04211-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Taeko Yonekawa, Akira Endo, Hirofumi Nakano, Joe Lee, Lydia Eccersley, Hena Baig, Eric Lewis, and Taku Fujii are employed by GSK and hold financial equities in GSK. Tomoaki Fujisaki, Kohmei Kubo, Yasushi Hiramatsu, and Ryosuke Ogawa declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}